ERBB2 and breast cancer: Disitamab vedotin, an ADC targeting HER2, has shown clinical efficacy in HER2+ and HER2-low BC, both as a single agent and in combination with other therapies.40 Ongoing trials are evaluating its effectiveness in patients with advanced HER2-low and metastatic HR+ BC.